Results 171 to 180 of about 103,961 (275)

Incidence, severity and potential pathomechanism of immune‐related pruritus in melanoma patients undergoing immune checkpoint inhibitor therapy

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and objectives Pruritus is a frequent cutaneous immune‐related adverse event (irAE) associated with immune checkpoint inhibitors (ICI), impacting patients' quality of life. This study investigates the incidence, severity and management of pruritus in melanoma patients treated with ICI.
Andrea Roggo, Nikolina Ivanovic, Patrick Turko, Lukas Kraehenbuehl, Mitchell Levesque, Reinhard Dummer, Barbara Meier‐Schiesser   +6 more
wiley   +1 more source

Nivolumab-induced Limbic Encephalitis in Gastric Cancer: A Case Report and Literature Review. [PDF]

Cancer Diagn Progn
Sumiyoshi S, Kubota T, Inoue H, Takabatake K, Nishibeppu K, Kosuga T, Konishi H, Fujiwara H, Shiozaki A.   +8 more
europepmc   +1 more source

Concurrent Nivolumab-Induced Myocarditis and Myasthenia Gravis: A Case Report. [PDF]

Case Rep Oncol Med
Gupta R, Plumber N, Lee J, Sivasubramanian BP, Kyhan ME, Singh H, Gupta S.   +6 more
europepmc   +1 more source

Clinical Significance of Anti‐Atezolizumab Antibodies in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab

Hepatology Research, EarlyView.
ABSTRACT Aim Systemic therapy is required for unresectable hepatocellular carcinoma (HCC). Atezolizumab plus bevacizumab (ATZ/BEV) is the recommended first‐line treatment for HCC; however, the development of anti‐drug antibodies (ADAs) against ATZ may impair its therapeutic efficacy. Although ADAs have been reported in other cancers treated with immune
Keishi Ouchi, Jun Inoue, Masashi Ninomiya, Mio Tsuruoka, Kosuke Sato, Kotaro Doi, Kengo Watanabe, Tomoya Sasazaki, Atsushi Masamune   +8 more
wiley   +1 more source

Nivolumab plus chemotherapy in Asian people with advanced or recurrent stomach or gastroesophageal junction cancer (ATTRACTION-4 study): a plain language summary. [PDF]

Future Oncol
Chen LT, Kang YK, Ryu MH, Oh DY, Oh SC, Rha SY, Lee KW, Omori T, Shitara K, Sakuramoto S, Chung IJ, Yamaguchi K, Kato K, Sym SJ, Kadowaki S, Tsuji K, Chen JS, Bai LY, Oh SY, Choda Y, Yasui H, Takeuchi K, Hirashima Y, Hagihara S, Boku N.   +24 more
europepmc   +1 more source

A case report of cerebral vasculitis induced by ipilimumab with nivolumab in a patient with metastatic renal cell carcinoma. [PDF]

Front Immunol
Palacka P, Málek T, Makovník M, Felediová R, Rychlý B, Kolníková G.   +5 more
europepmc   +1 more source

Mucous Membrane Pemphigoid After Anti‐PD‐1 Therapy: Risk‐Stratified Management and Treatment Outcomes

International Journal of Dermatology, EarlyView.
ABSTRACT Mucous membrane pemphigoid (MMP) following anti‐programmed cell death‐1 (PD‐1) therapy is rare but increasingly reported. Management of high‐ and low‐risk MMP in this setting and the potential oncologic trade‐offs remain poorly defined. We performed a narrative synthesis of all published cases of anti‐PD‐1‐associated MMP, following MEDLINE ...
Serena Dienes, Negar Esfandiari, Steven Daveluy   +2 more
wiley   +1 more source

An Image-Guided Combination Strategy: Immediate Hepatic Arterial Infusion of Nivolumab Following Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma. [PDF]

Cancers (Basel)
Zhang S, Zheng Z, Zhang C, Liu X, Shi X, Ma W.   +5 more
europepmc   +1 more source

Authors' Reply to Letter to the Editor: Sequential Ramucirumab Plus Docetaxel After PD‐1 Inhibitors

Cancer Science, EarlyView.
Kinnosuke Matsumoto, Yujiro Naito, Takayuki Shiroyama   +2 more
wiley   +1 more source

Immune checkpoint inhibitor cardiomyotoxicity: a case series of five patients and development of a clinical management algorithm

Internal Medicine Journal, EarlyView.
Abstract Immune checkpoint inhibitor (ICI) therapies have revolutionised the management of a range of malignancies. However, the syndrome of ICI induced cardiomyotoxicity, also reported as triple “M” syndrome (myasthenia gravis, myositis and myocarditis) is an unfortunate severe consequence in up to 1%–2% of patients receiving ICI, with an associated ...
S. Z. Xie, J. E. Salem, A. Nagrial, A. Menzies, L. Thomas, S. Ramanathan, L. J. Berglund, S. C. Sasson, A. C. Grey, R. Habib, M. Wong, M. S. Carlino, B. Jeffrey, J. Mo, M. W. Lin   +14 more
wiley   +1 more source